Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Clinical trial updates for CTCL: ARGX-110 and mogamulizumab

Martine Bagot • 18 Jan 2019
ASH 2018
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases T-Cell Lymphoma Antibodies ARGX-110 Mogamulizumab Vorinostat
MAVORIC

Martine Bagot, MD, PhD, of the Saint Louis Hospital, Paris, France, discusses two clinical trials for cutaneous T-cell lymphoma (CTCL): the Phase I/II study (NCT01813539) assessing the role of ARGX-110, a CD70-directed monoclonal antibody, and the Phase III MAVORIC study (NCT01728805) examining the effect of mogamulizumab. Prof. Bagot speaks at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, on the safety, efficacy and tolerability of these treatments.

More from Martine Bagot

1:05
Updates on the TELLOMAK trial
Martine Bagot • 15 Oct 2021
0:40
MAVORIC: long-term clinical benefit of mogamulizumab in patients with CTCL
Martine Bagot • 15 Oct 2021
0:54
Mogamulizumab-associated rash in CTCL
Martine Bagot • 15 Oct 2021
0:32
The future of CTCL therapy
Martine Bagot • 15 Oct 2021

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals